Buscar en
Revista Española de Medicina Nuclear e Imagen Molecular (English Edition)
Toda la web
Inicio Revista Española de Medicina Nuclear e Imagen Molecular (English Edition) Development of a leakage monitoring system in isolated limb perfusion with porta...
Journal Information
Vol. 40. Issue 1.
Pages 4-11 (January - February 2021)
Share
Share
Download PDF
More article options
Visits
3
Vol. 40. Issue 1.
Pages 4-11 (January - February 2021)
Original Article
Development of a leakage monitoring system in isolated limb perfusion with portable gamma camera
Desarrollo de un protocolo de monitorización de fuga en perfusión de miembro aislado con gammacámara portátil
Visits
3
A. Agudo Martíneza,
Corresponding author
, C. Calvo Moróna, T. Cambil Molinaa, F.J. García Gómeza, P.A. de la Riva Pereza, L. de la Cruz Merinob, O. Araji Tilianic, J.A. Terrón Leónd, J. Castro Montañoa
a Servicio de Medicina Nuclear. Hospital Universitario Virgen Macarena, Sevilla, Spain
b Servicio de Oncología Médica, Hospital Universitario Virgen Macarena, Sevilla, Spain
c Servicio de Cirugía Cardiovascular, Hospital Universitario Virgen Macarena, Sevilla, Spain
d Servicio de Radiofísica, Hospital Universitario Virgen Macarena, Sevilla, Spain
This item has received
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Figures (5)
Show moreShow less
Tables (5)
Table 1. Values of the means of the counts registered in each of the simulations.
Table 2. F(%) calculated in the 5 simulations without taking into account radioactive decay (Eq. 1) and taking radioactive decay into account (Eq. 2).
Table 3. Comparison of the means of the F(%) calculated in the 5 simulations with Eq. 1 and Eq. 2 and the theoretical F(%).
Table 4. Registry of the doses administered (Ac and Ae), time between the calibration of Ac and its injection, time between the administration of Ac and Ae and maximum and minimum leakage of each isolated limb perfusion (ILP).
Table 5. Relationship of patients with the grade of local post-treatment toxicity and the maximum F(%) of their perfusion procedures.
Show moreShow less
Abstract

Isolated limb perfusion (ILP) is a method for treating unresectable lesions of limbs in patients with melanoma or sarcoma by using high doses of tumor necrosis factor alpha and melphalan. This high doses can result in high systemic toxicity if there is a drug leak from the isolated circulation of the limb to the systemic. This makes it imperative to monitor the leakage rate (F(%)) during the infusion, currently performed with radiotracers. The objective of this work was to develop a leakage monitoring protocol as accurate as possible to ensure safe ILP.

Material and method

We built a phantom with three compartments (body, limb and precordial area) and a high sensitivity collimator fitted to a portable gamma camera. We simulate ILP with scheduled leaks every 10 min from 1% to 9% (theorical F(%)). We mesured F(%) using two equation: one is the proposed in the literature and another corrected by decay of the radioisotope. We test the optimal radiopharmaceutical doses to minimize the detector dead time error and compare F(%) mesured by both equations regarding the theoretical F(%).

The leakage monitoring protocol was used in 17 ILP of 16 patients and an analysis of the recorded data was performed.

Results

We found significant differences between F(%) mesured using the first equation and theoretical F(%), obtaining results very adjusted to the theorical after applying the decay correction.

Conclusions

the decay correction of the radioisotope is a simple manner to carry out the procedure more safely, reducing the error in the calculation of F(%).

Keywords:
Leakage monitoring
Isolated limb perfusion
Tumour necrosis factor alfa
Melphalan
Resumen

La perfusión de miembro aislado (PMA) es un método para tratamiento de extremidades con lesiones irresecables de pacientes con melanoma o sarcoma. Se usan altas dosis de factor de necrosis tumoral alfa y melfalán que pueden provocar toxicidad sistémica severa en caso de fuga del fármaco desde la circulación aislada de la extremidad a la sistémica. Esto hace imperativo monitorizar el porcentaje de fuga (F(%)) durante la perfusión, actualmente realizado con radiotrazadores. El objetivo de este trabajo fue elaborar un protocolo de monitorización de fuga lo más exacto posible que garantizara PMA seguras.

Material y método

Construimos un fantoma con tres compartimentos (cuerpo, extremidad y área precordial) y un colimador de alta sensibilidad adaptable a una gammacámara portátil. Simulamos PMA con fugas programadas cada 10 minutos del 1% al 9% (F(%) teóricos). Medimos estos F(%) mediante dos ecuaciones: una propuesta en la literatura y otra corregida por decay del radioisótopo. Testamos las dosis de radiofármaco óptimas para minimizar el error por tiempo muerto del detector y comparamos los F(%) medidos según las dos ecuaciones con los F(%) teóricos. El protocolo de monitorización de fuga se utilizó en 17 PMA de 16 pacientes realizándose un análisis de los datos registrados.

Resultados

Encontramos diferencias significativas entre los F(%) medidos con la primera ecuación y los F(%) teóricos, obteniéndose resultados muy ajustados a los teóricos al aplicar la corrección por decay.

Conclusiones

La corrección por decay del radioisótopo es una manera simple de realizar el procedimiento de forma más segura disminuyendo el error en el cálculo de F(%).

Palabras clave:
Control fuga
Perfusión miembro aislado
Factor de necrosis tumoral alfa
Melfalán

Article

These are the options to access the full texts of the publication Revista Española de Medicina Nuclear e Imagen Molecular (English Edition)
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Revista Española de Medicina Nuclear e Imagen Molecular (English Edition)

Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
Article options
Tools
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

Quizás le interese:
10.1016/j.remnie.2023.07.003
No mostrar más